Member Info for Rockefellow

Directors are insiders.

Good comment.The buyers are there but the sellers for whatever reason keep coming.All Puretech can do is keep building value.

It was a last minute surge in Wood towards 80p that got Puretech kicked out of the FTSE 250 .Now 25p

Exciting times ahead.IMHO.DYOR.NIAI

Miles Dixon never changed his target following Phase 2b LYT100 trial.Maybe he should reassess modeling Pure funding phase three and taking to market.

Must be soon.No point in initiating unless very detailed..with roadshows planned.

She did indeed.the right team,finance and projects are in place.as well as new stuff to come.

Puretech could become a FTSE 100 company over the next 5 years.IMHO DYOR.

We await UBS .Then maybe a US Corporate Broker.

Https://www.biotechtv.com/post/puretech-health-december-18-2024

Agreed!

Several new projects have not been revealed yet.Each I assume has $1bn to $10bn value potential.

I would value LYT100 at $2.5bn going it alone.Roche paid $8.3bn for Pirfenidone.IMHO DYOR

Https://www.bizjournals.com/boston/news/2024/03/22/karuna-puretech-seaport-cns.html

Seaport ..’Karuna on steroids ‘..Is how Daphne Zohar described just over a year ago.Has the potential to be worth over $10bn in coming years.IMHO DYOR.

Glyph has an addressable market of over $100bn pa in years to come ..optimising drugs.Seaport is going to be a red hot IPO

Initiation of coverage must be soon.

Https://www.biopharmadive.com/news/cobenfy-bristol-myers-sales-schizophrenia-drug-launch/739410/

Https://www.fiercebiotech.com/biotech/akeros-stock-doubles-failed-midphase-mash-trial-hits-long-term-analysis

And they raise $408m in an over subscribed offering.The appetite is there for good projects.

A deal with Royalty Pharma was discussed in the results webcast in September.A a Karuna like $500m deal for 5to10pc is perfectly possible.With Karuna a 3pc royalty was monetized.potential sales may be a little less than for Cobenfy but 100pc of revenues not 3pc.